RT Journal Article
T1 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
A1 Alfonso, Fernando
A1 Pérez-Vizcayno, María José
A1 Cuesta, Javier
A1 García Del Blanco, Bruno
A1 García-Touchard, Arturo
A1 López-Mínguez, José Ramón
A1 Masotti, Mónica
A1 Zueco, Javier
A1 Cequier, Angel
A1 Velázquez, Maite
A1 Moreno, Raúl
A1 Mainar, Vicente
A1 Domínguez, Antonio
A1 Moris, Cesar
A1 Molina, Eduardo
A1 Rivero, Fernando
A1 Jiménez-Quevedo, Pilar
A1 Gonzalo, Nieves
A1 Fernández-Pérez, Cristina
A1 RIBS IV Study Investigators (Under the Auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology), 
K1 drug-eluting ballon(s)
K1 drug-eluting stent(s)
K1 everolimus-eluting stent(s)
K1 in-stent restenosis
AB This study sought to compare the long-term safety and efficacy of drug-eluting balloons (DEB) and everolimus-eluting stents (EES) in patients with in-stent restenosis (ISR) of drug-eluting stents (DES). Treatment of patients with DES-ISR remains a challenge. The RIBS IV (Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloons vs Everolimus-Eluting Stents) trial is a prospective multicenter randomized clinical trial comparing DEB and EES in patients with DES-ISR. The pre-specified comparison of the 3-year clinical outcomes obtained with these interventions is the main objective of the present study. A total of 309 patients with DES-ISR were randomized to DEB (n = 154) or EES (n = 155). At angiographic follow-up, the in-segment minimal lumen diameter was larger in the EES arm (2.03 ± 0.7 mm vs. 1.80 ± 0.6 mm; p 1 year) target lesion revascularization (2.6% vs. 4%) and target vessel revascularization (4% vs. 6.6%) was similar in the 2 arms. Rates of cardiac death (3.9% vs. 3.2%), myocardial infarction (2.6% vs. 4.5%), and stent thrombosis (1.3% vs. 2.6%) at 3 years were also similar in both arms. The 3-year clinical follow-up of this randomized clinical trial demonstrates that in patients with DES-ISR, EES reduce the need for repeat interventions compared with DEB. (Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloons vs Everolimus-Eluting Stents [RIBS IV]; NCT01239940).
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12505
UL http://hdl.handle.net/10668/12505
LA en
DS RISalud
RD Apr 18, 2025